Protein crystals for the delivery of biopharmaceuticals.
about
Crystal Polymorphism of Protein GB1 Examined by Solid-State NMR Spectroscopy and X-ray DiffractionCrystallographic characterization of two novel crystal forms of human insulin induced by chaotropic agents and a shift in pHTowards protein crystallization as a process step in downstream processing of therapeutic antibodies: screening and optimization at microbatch scaleCrystallization of recombinant human growth hormone at elevated pressures: pressure effects on PEG-induced volume exclusion interactions.Polymorphic Protein Crystal Growth: Influence of Hydration and Ions in Glucose Isomerase.Human insulin polymorphism upon ligand binding and pH variation: the case of 4-ethylresorcinol.Solid-state protein formulations.Large-scale crystallization of proteins for purification and formulation.In Quest for Improved Drugs against Diabetes: The Added Value of X-ray Powder Diffraction Methods.Continuous Manufacturing of Recombinant Therapeutic Proteins: Upstream and Downstream Technologies.Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation.Continuous Crystallization of Proteins in a Tubular Plug-Flow Crystallizer.Structural studies of human insulin cocrystallized with phenol or resorcinol via powder diffraction.Protein-Containing Multilayer Capsules by Templating on Mesoporous CaCO3 Particles: POST- and PRE-Loading Approaches.X-ray transparent microfluidic platforms for membrane protein crystallization with microseeds.A comparative study of monoclonal antibodies. 1. Phase behavior and protein-protein interactions.The role of non-specific interactions in a patchy model of protein crystallizationMicroparticulate biomolecules by mild CaCO3templating
P2860
Q27649177-A7D9C3DF-5CCD-4712-A2F2-4A4D6630A79DQ27649366-CF13BE24-396D-4A63-8202-9F5649557FE2Q28744644-C7B46936-FE9E-4F5A-A609-971FA84F35A2Q33447064-4E7C3762-893A-4718-88F2-7F5EEC657ABCQ33771640-327D4615-1C2C-4754-862F-6B31507AD749Q35991412-20F7ADF5-9110-4B17-B59A-B0956EAA1DDBQ38309879-64A164DC-BAE5-4464-B4B8-92D84D535080Q38363126-C41A145F-66D7-43A2-ABB9-5E3DCFCBF5B1Q38614384-413821B4-8221-430C-9F77-66B9043EDA2AQ39164854-1E03CE64-93F3-43E4-86E0-E31F7A39DEC0Q39279201-E580EA77-D153-4CE3-BC2E-E428063F20EFQ43179966-7B0B4744-0DE0-4FF9-BD15-1861F1EFD29BQ44291286-DD91CCBD-EB9D-45B4-ABFE-5079ABD09269Q49117308-3231A8E9-ADE4-4F4F-8589-0D17C2731F3FQ51419266-ED65630C-9439-4556-86B9-D804BD6693E5Q55239928-AD6886E0-03E2-4676-A282-41165D344FAFQ56931067-747B8144-9062-49DA-B054-BFE210F42018Q57364624-165057CC-645C-45DC-A87C-7FB5009C922C
P2860
Protein crystals for the delivery of biopharmaceuticals.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Protein crystals for the delivery of biopharmaceuticals.
@ast
Protein crystals for the delivery of biopharmaceuticals.
@en
type
label
Protein crystals for the delivery of biopharmaceuticals.
@ast
Protein crystals for the delivery of biopharmaceuticals.
@en
prefLabel
Protein crystals for the delivery of biopharmaceuticals.
@ast
Protein crystals for the delivery of biopharmaceuticals.
@en
P2093
P2860
P356
P1476
Protein crystals for the delivery of biopharmaceuticals.
@en
P2093
Alexey L Margolin
Chandrika P Govardhan
Chu W Jung
Sujit K Basu
P2860
P304
P356
10.1517/14712598.4.3.301
P407
P577
2004-03-01T00:00:00Z